-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 9, Fosun Pharma announced that it will establish a joint venture with BioNtech in China to realize the localized production and commercialization of mRNA COVID-19 vaccine products.
Fosun Pharma and BioNtech signed the mRNA new crown vaccine license agreement on March 13, 2020""), and was authorized to exclusively develop and commercialize the latter's proprietary mRNA in the Greater China Region (including Mainland China, Hong Kong, Macao and Taiwan) Vaccine products against the new coronavirus developed by the technology platform.
In order to further implement the "License Agreement Amendment One" related to the localized production of mRNA for the new crown vaccine, the two parties today announced the signing of the "Terms", the establishment of a joint venture company, and an agreement that Fosun Pharmaceutical Industry should provide an annual production capacity of up to 1 billion doses of mRNA The new crown vaccine production facility, and the facility will be injected into the joint venture as part of the investment.
Regarding the subsequent commercialization of the vaccine, it was agreed that the joint venture company would hire an affiliate of Fosun Pharmaceutical Industry as the CSO to provide marketing and sales services for the mRNA COVID-19 vaccine in China (excluding Hong Kong, Macao and Taiwan), and pay the CSO accordingly.
